Search research articles
Contact Us
Filters
Showing results (11-20 of 17) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 17 results.
Cell Systems
|
March 30, 2018
Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas
Franz X Schaub, Varsha Dhankani, Ashton C Berger, et al.
Ebiomedicine
|
September 14, 2020
BET, SRC, and BCL2 family inhibitors are synergistic drug combinations with PARP inhibitors in ovarian cancer
Goldie Y L Lui, Reid Shaw, Franz X Schaub, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 31, 2018
Functional Precision Medicine Identifies Novel Druggable Targets and Therapeutic Options in Head and Neck Cancer
Chang Xu, Olga Nikolova, Ryan S Basom, et al.
Blood Advances
|
February 19, 2025
Assessing AML-based risk criteria in patients with accelerated/blast-phase MPN treated with less-intensive therapy
Reid Shaw, James J Yoon, Hannah Johnston, et al.
Cancer Discovery
|
March 24, 2017
Personalized <i>In Vitro</i> and <i>In Vivo</i> Cancer Models to Guide Precision Medicine
Chantal Pauli, Benjamin D Hopkins, Davide Prandi, et al.
The Journal of Experimental Medicine
|
May 5, 2022
Inhibition of FGF receptor blocks adaptive resistance to RET inhibition in CCDC6-RET-rearranged thyroid cancer
Renuka Raman, Jacques A Villefranc, Timothy M Ullmann, et al.
Nature Communications
|
June 21, 2018
Patient derived organoids to model rare prostate cancer phenotypes
Loredana Puca, Rohan Bareja, Davide Prandi, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 17) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 17 results.
Cell Systems
|
March 30, 2018
Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas
Franz X Schaub, Varsha Dhankani, Ashton C Berger, et al.
Ebiomedicine
|
September 14, 2020
BET, SRC, and BCL2 family inhibitors are synergistic drug combinations with PARP inhibitors in ovarian cancer
Goldie Y L Lui, Reid Shaw, Franz X Schaub, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 31, 2018
Functional Precision Medicine Identifies Novel Druggable Targets and Therapeutic Options in Head and Neck Cancer
Chang Xu, Olga Nikolova, Ryan S Basom, et al.
Blood Advances
|
February 19, 2025
Assessing AML-based risk criteria in patients with accelerated/blast-phase MPN treated with less-intensive therapy
Reid Shaw, James J Yoon, Hannah Johnston, et al.
Cancer Discovery
|
March 24, 2017
Personalized <i>In Vitro</i> and <i>In Vivo</i> Cancer Models to Guide Precision Medicine
Chantal Pauli, Benjamin D Hopkins, Davide Prandi, et al.
The Journal of Experimental Medicine
|
May 5, 2022
Inhibition of FGF receptor blocks adaptive resistance to RET inhibition in CCDC6-RET-rearranged thyroid cancer
Renuka Raman, Jacques A Villefranc, Timothy M Ullmann, et al.
Nature Communications
|
June 21, 2018
Patient derived organoids to model rare prostate cancer phenotypes
Loredana Puca, Rohan Bareja, Davide Prandi, et al.
Page
of 2